Literature DB >> 10617611

Seven non-contiguous intracellular residues of the lutropin/choriogonadotropin receptor dictate the rate of agonist-induced internalization and its sensitivity to non-visual arrestins.

K Nakamura1, X Liu, M Ascoli.   

Abstract

The amino acid sequences of the human (h) and rat (r) lutropin/choriogonadotropin receptors (LHR) are 87% identical, but the rate of agonist-induced internalization of the hLHR is approximately 7 times faster than that of the rLHR. Chimeras of the hLHR and the rLHR showed that this rate is dictated by the serpentine domain and the cytoplasmic tail. Further mutational analysis identified seven residues, two adjacent residues in the second intracellular loop (Val/Gln in the rLHR and Ile/His in the hLHR), four non-contiguous residues in the third intracellular loop (Arg/Gln/Thr/Pro in the rLHR and Lys/Arg/Met/Thr in the hLHR), and one in the C-terminal tail (Leu in the rLHR and Phe in the hLHR), that are necessary and sufficient to impart the slow rate of internalization of the rLHR and the fast rate of internalization of the hLHR. The internalization of the rLHR and the hLHR display different sensitivities to the non-visual arrestins. Therefore, we also tested if the simultaneous exchange of these seven residues resulted in the exchange of this property. Since this was found to be the case, we propose that these seven residues identified here form a non-visual arrestin-binding site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617611     DOI: 10.1074/jbc.275.1.241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

2.  A constitutively active mutant of the human lutropin receptor (hLHR-L457R) escapes lysosomal targeting and degradation.

Authors:  Colette Galet; Mario Ascoli
Journal:  Mol Endocrinol       Date:  2006-06-27

Review 3.  β-Arrestin-mediated receptor trafficking and signal transduction.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  Trends Pharmacol Sci       Date:  2011-06-15       Impact factor: 14.819

4.  The role of Rab5a GTPase in endocytosis and post-endocytic trafficking of the hCG-human luteinizing hormone receptor complex.

Authors:  Thippeswamy Gulappa; Christine L Clouser; K M J Menon
Journal:  Cell Mol Life Sci       Date:  2010-11-23       Impact factor: 9.261

5.  Dynamic kisspeptin receptor trafficking modulates kisspeptin-mediated calcium signaling.

Authors:  Le Min; Kathleen Soltis; Ana Claudia S Reis; Shuyun Xu; Wendy Kuohung; Manisha Jain; Rona S Carroll; Ursula B Kaiser
Journal:  Mol Endocrinol       Date:  2013-12-02

6.  Arrestin-3 is essential for the activation of Fyn by the luteinizing hormone receptor (LHR) in MA-10 cells.

Authors:  Colette Galet; Mario Ascoli
Journal:  Cell Signal       Date:  2008-06-19       Impact factor: 4.315

7.  Computational modelling of bovine ovarian follicle development.

Authors:  Dagmar Iber; Christian De Geyter
Journal:  BMC Syst Biol       Date:  2013-07-15

8.  The stem cell-expressed receptor Lgr5 possesses canonical and functionally active molecular determinants critical to β-arrestin-2 recruitment.

Authors:  Joshua C Snyder; Lauren K Rochelle; Larry S Barak; Marc G Caron
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  The C-terminal Phosphorylation Sites of eel Follicle-Stimulating Hormone Receptor are Important Role in the Signal Transduction.

Authors:  Jeong-Min Kim; Munkhzaya Byambaragchaa; Myung-Hwa Kang; Kwan-Sik Min
Journal:  Dev Reprod       Date:  2018-06-30

10.  Integration of GPCR Signaling and Sorting from Very Early Endosomes via Opposing APPL1 Mechanisms.

Authors:  Silvia Sposini; Frederic G Jean-Alphonse; Mohammed A Ayoub; Affiong Oqua; Camilla West; Stuart Lavery; Jan J Brosens; Eric Reiter; Aylin C Hanyaloglu
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.